Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience

被引：10

作者：

Antonioli, Elisabetta ^{[1
]}

Staderini, Michela ^{[1
]}

Pilerci, Sofia ^{[1
]}

Perfetto, Federico ^{[2
]}

Cappelli, Francesco ^{[2
]}

Allinovi, Marco ^{[2
,3
]}

Nozzoli, Chiara ^{[4
]}

Attucci, Irene ^{[1
]}

Buzzichelli, Alessandra ^{[1
]}

Messeri, Maria ^{[1
]}

Bosi, Alberto ^{[1
]}

机构：

[1] Careggi Univ Hosp, Haematol Unit, Largo Brambilla 3, I-50134 Florence, Italy

[2] Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Florence, Italy

[3] Careggi Hosp, Nephrol Dialysis & Transplantat Unit, Florence, Italy

[4] Careggi Univ Hosp, Cell Therapy & Transfus Med Unit, Florence, Italy

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 13期

关键词：

REFRACTORY MULTIPLE-MYELOMA; MONOTHERAPY;

D O I：

10.1080/10428194.2020.1802452

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3255 / 3258

页数：4

共 50 条

[21] Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)
Anna Mele
Eleonora Prete
Clara De Risi
Stefania Citiso
Giuseppina Greco
Antonietta Pia Falcone
Grazia Sanpaolo
Giuseppe Mele
Angela Giannotta
Carolina Vergine
Giovanni Reddiconto
Giulia Palazzo
Sabrina Sabatelli
Candida Germano
Rosanna Miccolis
Paola Curci
Gaetano Palumbo
Massimo Offidani
Rita Rizzi
Nicola Cascavilla
Domenico Pastore
Nicola Di Renzo
Patrizio Mazza
Giuseppe Tarantini
Attilio Guarini
Silvana Capalbo
Giorgina Specchia
Antonino Greco
Rosa De Francesco
Silvia Sibilla
Lorenzo Tonialini
Maria Rosaria Morciano
Vincenzo Pavone
Annals of Hematology, 2021, 100 : 429 - 436
[22] Longterm Lenalidomide therapy in relapsed or refractory multiple myeloma patients - a single-center experience
Denecke, B.
Bross-Bach, U.
Kanz, L.
Weisel, K.
ONKOLOGIE, 2010, 33 : 248 - 248
[23] EFFICACY AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL LIFE EXPERIENCE
Soyer, N.
Patir, P.
Uysal, A.
Duran, M.
Unal, H. D.
Tombuloglu, M.
Sahin, F.
Vural, F.
Saydam, G.
LEUKEMIA RESEARCH, 2016, 49 : S36 - S36
[24] Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
Antonioli, Elisabetta
Pilerci, Sofia
Attucci, Irene
Buda, Gabriele
Gozzetti, Alessandro
Candi, Veronica
Simonetti, Federico
Del Giudice, Maria Livia
Ciofini, Sara
Staderini, Michela
Grammatico, Sara
Buzzichelli, Alessandra
Messeri, Maria
Bocchia, Monica
Galimberti, Sara
Vannucchi, Alessandro. M. M.
FRONTIERS IN ONCOLOGY, 2023, 13
[25] Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis
Stork, Martin
Spicka, Ivan
Radocha, Jakub
Minarik, Jiri
Jelinek, Tomas
Jungova, Alexandra
Pavlicek, Petr
Pospisilova, Lenka
Sedlak, Frantisek
Straub, Jan
Pika, Tomas
Knechtova, Zdenka
Fidrichova, Anna
Boichuk, Ivanna
Sevcikova, Sabina
Maisnar, Vladimir
Hajek, Roman
Pour, Ludek
ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1501 - 1511
[26] Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Martin Stork
Ivan Spicka
Jakub Radocha
Jiri Minarik
Tomas Jelinek
Alexandra Jungova
Petr Pavlicek
Lenka Pospisilova
Frantisek Sedlak
Jan Straub
Tomas Pika
Zdenka Knechtova
Anna Fidrichova
Ivanna Boichuk
Sabina Sevcikova
Vladimir Maisnar
Roman Hajek
Ludek Pour
Annals of Hematology, 2023, 102 : 1501 - 1511
[27] Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
Wong, Xin Yi
Chng, Wee Joo
Aziz, Mohamed Ismail Abdul
Ng, Kwong
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 207 - 215
[28] Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
Conticello, Concetta
Romano, Alessandra
Del Fabro, Vittorio
Martino, Enrica Antonia
Calafiore, Valeria
Sapienza, Giuseppe
Leotta, Valerio
Parisi, Marina Silvia
Markovic, Uros
Garibaldi, Bruno
Leotta, Salvatore
Cotzia, Emilia
Innao, Vanessa
Mannina, Donato
Neri, Santo
Musso, Maurizio
Scalone, Renato
Cangialosi, Clotilde
Acquaviva, Francesco
Cardinale, Giovanni
Merenda, Anxur
Maugeri, Cinzia
Uccello, Giuseppina
Poidomani, Massimo
Longo, Giuseppe
Carlisi, Melania
Tibullo, Daniele
Di Raimondo, Francesco
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
[29] Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study
Bernard Regidor
Marissa-Skye Goldwater
Jessica Wang
Sean Bujarski
Regina Swift
Benjamin Eades
Marsiye Emamy-Sadr
Shahrooz Eshagian
Gary Schwartz
Tanya M. Spektor
James R. Berenson
Annals of Hematology, 2021, 100 : 2061 - 2070
[30] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary E.
Feng, Huaibao
Brun, Nikolai Constantin
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →